149. Hemiconvulsion hemiplegia epilepsy syndrome Clinical trials / Disease details
Clinical trials : 25 / Drugs : 35 - (DrugBank : 13) / Drug target genes : 16 - Drug target pathways : 22
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-194633 | 05/6/2019 | 15/02/2019 | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study of T-817MA in Post-stroke Patients Undergoing Rehabilitation for Upper Limb Hemiplegia | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study of T-817MA in Post-stroke Patients Undergoing Rehabilitation for Upper Limb Hemiplegia | Patients with upper limb hemiplegia after cerebral infarction or cerebral hemorrhage (other than subarachnoid hemorrhage) | Intervention name : T-817MA INN of the intervention : Edonerpic Dosage And administration of the intervention : Oral Multiple Dose Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | FUJIFILM Toyama Chemical Co., Ltd | NULL | complete | 20 | 84 | BOTH | 65 | Phase 2 | Japan |
| 2 | JPRN-JapicCTI-173615 | 22/8/2017 | 15/06/2017 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization | Epilepsy and epilepsy syndrome | Intervention name : ucb 34714 INN of the intervention : Brivaracetam Dosage And administration of the intervention : Oral administration Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | NULL | recruiting | 16 | 80 | BOTH | 444 | Phase 3 | Japan, Asia except Japan |
| 3 | JPRN-JapicCTI-153104 | 18/3/2016 | 22/12/2015 | AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY | AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY | Epilepsy and epilepsy syndrome | Intervention name : SPM927 INN of the intervention : Lacosamide Dosage And administration of the intervention : oral administration Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | NULL | complete | 4 | BOTH | 239 | Phase 3 | Japan, Asia except Japan, North America, Europe, Oceania | |
| 4 | JPRN-JapicCTI-153103 | 08/12/2015 | 22/12/2015 | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY | Epilepsy and epilepsy syndrome | Intervention name : SPM927 INN of the intervention : Lacosamide Dosage And administration of the intervention : oral administration Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | NULL | complete | 4 | BOTH | 242 | Phase 3 | Japan, Asia except Japan, North America, Europe, Oceania | |
| 5 | NCT02408354 (ClinicalTrials.gov) | April 15, 2015 | 24/3/2015 | Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood | Etude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant HEMIHEP | Alternating Hemiplegia of Childhood | Drug: Triheptanoin;Drug: Placebo | Institut National de la Santé Et de la Recherche Médicale, France | NULL | Completed | 15 Years | N/A | All | 10 | Phase 2 | France |
| 6 | NCT01623622 (ClinicalTrials.gov) | July 2012 | 18/6/2012 | Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke | A Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After Stroke | Severe Upper Limb Hemiplegia | Drug: HC-58;Drug: Placebo | Asahi Kasei Pharma Corporation | NULL | Completed | 20 Years | N/A | All | 270 | Phase 2 | Japan |